About Liminal BioSciences
Liminal BioSciences develops small molecule treatments targeting GPR84 receptor for inflammatory bowel disease and other fibrotic conditions alongside plasma-derived protein therapies.
📍 Location & Offices
📋 Request a Quote
Send your requirements directly to Liminal BioSciences. Response typically within 48 hours.
Company Info
TypePublic
StockLMNL (NASDAQ)
Founded2019
Employees200
Revenue$42M
HQLaval, Canada
